ONCOLYTICS BIOTECH INC

Oncolytics insider buying signals growing confidence in its reovirus platform, with promising market access and clinical milestones but notable risks.

Oncolytics Biotech’s CEO and top execs are buying more shares—an insider confidence boost tied to its REOLYSIN pipeline, hinting at future growth despite current volatility.

Oncolytics’ CEO and senior execs buy shares, boosting confidence in its reovirus pipeline and upcoming Phase 2 results that could lift the low‑valuation biotech’s prospects.

Oncolytics insider buys reveal confidence after FDA Fast‑Track approval; investor insight on potential $200‑$400 M revenue and cautious strategy.

Oncolytics Biotech insider buying shows long‑term confidence in its reovirus platform, regulatory shift to Nevada, and patent expansion—signals to watch for future upside.